Personalis, Inc.
PSNLHealthcareNASDAQDiagnostics & Research · Last scanned Sep 8, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Personalis, Inc. focuses on Diagnostics & Research services and products. Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. With a market capitalization of $1.84B, it sits in small-cap territory. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample.
Market Cap
$1.84B
Beta
2.32
P/E (TTM)
—
P/E (Fwd)
-18.27
EPS (TTM)
$-1.09
EPS (Fwd)
$-0.94
ROE
-50.3%
ROA
-25.0%
Cash
$212.7M
Total Debt
$38.0M
Free CF
-$56.0M
52W Change
219.1%
Annual Financials
Cash vs Debt
Where PSNL stands vs its 150-day and 200-day moving averages
As of the August 27, 2026 close, PSNL finished 74.11% above its 150-day moving average ($9.81) and 78.47% above its 200-day moving average ($9.57). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PSNL overbought or oversold?
At the August 27, 2026 close, PSNL's RSI(14) was 72.4, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $212.7M in cash and $38.0M in debt, PSNL maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$56.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -50.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been relatively flat, moving from $65.0M (2022) to $69.6M (2025).
Personalis, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, PSNL has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Personalis, Inc. and its sector.